CheckMate 026: Why did Opdivo (nivolumab) fail in NSCLC?

September 1, 2016- Interviewed by Steven E. Greer, MD

In the wake of the news-making failure of CheckMate 026 of Bristol-Myers Squibb’s Opdivo (nivolumab) fail in NSCLC, we interviewed Siwen Hu-Lieskovan MD, PhD, an expert in immunotherapy, about the trial design. She believes that the trial design is the reason for failure rather than the drug not working. A second Phase 3 trial is underway now that is better designed, she thinks.

This entry was posted in - Biotech, - Pharma, Oncology, UCLA. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *